BGES Bio Bridge Science Inc (CE)

Bio-Bridge Science Inc. (OTCBB:BGES), a development-stage biotech company, announced today that its encouraging results for pharmacological and acute toxicity studies on its HIV therapeutic Vaccine (HIV-PV pseudovirus) on mice and monkeys will be a feature in the Corporate News section of Investor's Business Daily (IBD) today, plus Friday, February 10th and Monday, February 13th. The information is also available online in the "Corporate News" section of IBD at http://www.investors.com/corporatenews/ for the next two weeks. The vaccine, based on exclusive technology co-developed by CEO Liang Qiao, an associate professor at Loyola University Chicago's Stritch School of Medicine, targets infection in mucosal tissues, the first type of tissue attacked by HIV. Dr. Liang Qiao, Chairman and CEO of Bio-Bridge Science said, "We are pleased with the initial results of the pre-clinical trials for our HIV Vaccine. We hope to reach a larger audience of investors through publishing the information in Investor Business Daily in order to familiarize them with our company and the exciting technology that we are testing." About Bio-Bridge Science Bio-Bridge Science is a biotechnology firm focused on the development of vaccines with broad therapeutic and preventive applications. Through its wholly owned subsidiary in Beijing, Bio-Bridge is developing a promising new HIV Vaccine, that is expected to enter clinical trials in China in the very near future. The vaccine, based on exclusive technology co-developed by CEO Liang Qiao, an associate professor at Loyola University Chicago's Stritch School of Medicine, targets infection in mucosal tissues, the first type of tissue attacked by HIV. The Chinese government, mindful of the rapid expansion of AIDS in China has, through the "Green Mile Policy," acted to expedite the approval of domestically produced HIV Vaccines and has dramatically increased its spending on AIDS-related research. In accordance with this policy, Bio-Bridge expects to bring its therapeutic HIV Vaccine to market as early as 2008, far in advance of many other HIV Vaccines currently in development. Bio-Bridge is currently constructing a new $3 million state-of-the-art GMP research and manufacturing facility in Beijing, which is expected to be completed in early 2006. Forward-Looking Statements This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks defined in this document and in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof. Please refer to SEC filings for additional information and accompanying notes to financial statements.